Skip to main content
Lareb logo
  • About Lareb
  • News updates
  • Publications and overviews
  • Education and patient reporting
  • Teratology Information Service (TIS)
  • About Lareb
  • Research and collaborations
  • Contact

Meld een bijwerking van een:

Kies het type product waarover je een bijwerking wilt melden.

Vaccin Geneesmiddel of gezondheidsproduct zoals vitamine, supplement of kruidenpreparaat
/media/1auhenje/banner-homepage-2.png
  • Home
  • News updates
  • Lamotrigine and photosensitivity

Lamotrigine and photosensitivity

04-03-2020

Lees voor

The Netherlands Pharmacovigilance Centre Lareb received three reports of photosensitivity associated with the use of lamotrigine. Patients experienced an itchy skin rash on the skin that was exposed to sunlight. 

Lamotrigine is indicated for the treatment of several forms of epilepsy and bipolar disorders. Photosensitivity is not described in the Dutch Summary of Product Characteristics (SmPC) of lamotrigine. This association is described in a few cases in literature. In addition, the international database of the WHO also includes cases of photosensitivity associated with the use of lamotrigine. 

Lareb informed the Dutch Medicines Evaluation Board about these reports. The Dutch Medicines Evaluation Board will discuss this association within the European regulatory network. 

Read here the analysis of the reports.

Pharmacovigilance Centre Lareb
  • About Lareb
  • Research and collaborations
  • Contact
Search
  • News updates
  • Publications and overviews
More about
  • Education and patient reporting
  • Teratology Information Service (TIS)
logo
© Lareb. All Rights Reserved. 2026
Dutch | Cookies | Privacy | Disclaimer
Pharmacovigilance Centre Lareb
  • About Lareb
  • Research and collaborations
  • Contact
Search
  • News updates
  • Publications and overviews
More about
  • Education and patient reporting
  • Teratology Information Service (TIS)
logo
© Lareb. All Rights Reserved. 2026
Dutch | Cookies | Privacy Disclaimer

Wat vond je van deze informatie?

Toelichting

Let op: je ontvangt geen reactie. Heb je een vraag? Vul dan ons contactformulier in.